BTW, when I say "nobody" was talking about ending the filibuster, that's a slight exaggeration. There were voices out there pushing it early, just like some progressives wanted to go with reconciliation right away. But it wasn't on the agenda in the way it is today.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Latest from @adamcancryn on the internal Biden administration debate over an FDA commissioner, and concerns that Janet Woodcock is too close/sympathetic to pharmaceutical industry.
In 2009, when E&C Committee was writing its version of what became the the Affordable Care Act, Eshoo pushed to give biologics a longer "exclusivity" period.
Chairman Henry Waxman, who thought it was a giveaway to industry, opposed that strongly. Eshoo prevailed. (2)
As legislation moved through Congress, Waxman kept fighting to reduce that period. So did Obama, who agreed w/Waxman and was really worked up about it.
This exchange in particular deserves emphasis -- i.e., how the difficulty isn't any one thing.
So it's not supply or distribution. It's supply *and* distribution. With a different situation in every community. And conditions that will change with time.
Biden's strategy reflects this. It's got many small parts, no single one of which is a game-changer. But together they add up.
Or, at least, we hope they add up. The test will be execution.
One thing to put these ideas on a piece of paper. Another to put them into action.